达拉非尼治疗转移性非小细胞肺癌： 在BRAF V600E突变NSCLC患者中，达拉非尼联合曲美替尼的治疗方案能够显著延长患者的生存期，客观缓解率（ORR ...

非小细胞肺癌（NSCLC）是世界上最常见的恶性肿瘤之一。EGFR酪氨酸激酶抑制剂（EGFR-TKI）是表皮生长因子细胞受体突变（EGFR突变型）晚期NSCLC患者的首选一线治疗药物。不幸的是，药物耐药会不可避免地导致疾病进展。ALK和BRAF旁路信号 ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

引言结直肠癌（CRC）易发生肝转移，初始不可切除结直肠癌肝转移（CRLM）是临床处理中的难点。目前多项指南共识对 CRLM 的治疗做出推荐，同时临床研究结果的出炉也带来更多证据。2024 年 11 月，CAIRO5 研究事后分析结果公布[1]，为 ...

Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: About Boundless Bio ...